JonesResearch initiated coverage of Rapport Therapeutics (RAPP) with a Buy rating and $42 price target Rapport is a clinical-stage biopharmaceutical company developing therapies for the treatment of several central nervous system indications via its receptor associated protein platform, the analyst tells investors in a research note. The firm says the mid-2025 topline readout in refractory focal epilepsy to provide clinical validation for lead asset RAP-219 and the broader development platform is a reason to own the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.